



#### WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



# INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: C07K 14/47, C12N 15/12, 15/62, C07K 16/18, C12N 15/63, A01K 67/027, A61K 48/00

(11) International Publication Number:

WO 99/06545

A3

EP

(43) International Publication Date:

11 February 1999 (11.02.99)

(21) International Application Number:

PCT/EP98/04811

(22) International Filing Date:

31 July 1998 (31.07.98)

(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,

(30) Priority Data:

97 11 3306.1

I August 1997 (01.08.97)

Published

With international search report.

(71) Applicant (for all designated States except US): MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG


DER WISSENSCHAFTEN E.V. [DE/DE]; Berlin (DE).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): WANKER, Erich [AT/DE]; Leichhardtstrasse 61, D-14195 Berlin (DE). LEHRACH, Hans [AT/DE]; Lützelsteiner Weg 50, D-14195 Berlin (DE), SCHERZINGER, Eberhard [DE/DE]; Lützelsteiner Weg 52, D-14195 Berlin (DE). BATES, Gillian [GB/GB]; Division of Medical and Molecular Genetics, United Medical and Dental Schools, Guy's Hospital, Guy's Tower, 8th floor, London SEI 9RT (GB).
- (74) Agent: VOSSIUS & PARTNER; Postfach 86 07 67, D-81634 München (DE).

(88) Date of publication of the international search report: 5 August 1999 (05.08.99)

(54) Title: COMPOSITION AND METHOD FOR THE DETECTION OF DISEASES ASSOCIATED WITH AMYLOID-LIKE FIBRIL OR PROTEIN AGGREGATE FORMATION



### (57) Abstract

The present invention relates to novel compositions useful for elucidating the onset or progress of diseases of preferably neuronal origin associated with the formation of amyloid-like fibrils or protein aggregates. Further, the present invention relates to methods for monitoring said formation as well as to methods for identifying inhibitors of said formation. Additionally, the invention relates to inhibitors identified by the method of the invention as well as to pharmaceutical compositions comprising said inhibitors.

## FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
ΛM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
ΑT	Austria	FR	France	LU	Luxembourg	SN	Senegal
ΑU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
ΑZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GII	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
ВJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Isracl	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of Americ
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JР	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	Ϋ́U	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand	-3	ZJIII OUDWC
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## INTERNATIONAL SEARCH REPORT

Interna al Application No

PCT/EP 98/04811 CLASSIFICATION OF SUBJECT MATTER PC 6 C07K14/47 C12N IPC 6 C12N15/12 C12N15/62 C07K16/18 C12N15/63 A01K67/027 A61K48/00 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) IPC 6 C12N Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Category ° Citation of document, with Indication, where appropriate, of the relevant passages Relevant to claim No. χ WO 97 17445 A (CENTRE NAT RECH SCIENT 1,13,20 ; INST NAT SANTE RECH MED ) 15 May 1997 see page 3, line 7 - page 4, line 33 see page 14, line 10 - page 16, line 32; example 1 X C.A. GUTEKUNST ET AL., : "Identification 1-6,8,13and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies " PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 92, 1995, pages 8710-8714, XP002101176 cited in the application see page 8710 Further documents are listed in the continuation of box C. Patent family members are listed in annex. Special categories of cited documents : "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another "Y" document of particular relevance; the claimed invention citation or other special reason (as specified) cannot be considered to involve an inventive step when the document is combined with one or more other such docu-"O" document referring to an oral disclosure, use, exhibition or other means ments, such combination being obvious to a person skilled document published prior to the international filing date but later than the pnority date claimed in the art. "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 28 April 1999 21/05/1999 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,

Form PCT/ISA/210 (second sheet) (July 1992)

Fax: (+31-70) 340-3016

1

Mateo Rosell, A.M.



Internat I Application No PCT/EP 98/04811

Category °	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	TROTTIER Y ET AL: "POLYGLUTAMINE EXPANSION AS A PATHOLOGICAL EPITOPE IN HUNTINGTON'S DISEASE AND FOUR DOMINANT CEREBELLAR ATAXIAS" NATURE, vol. 378, no. 6555, 23 November 1995, pages 403-406, XP002009617 see the whole document and specially last paragraph	1-6,13
X	M.F. PERUTZ: "Glutamine repeats and inherited neurodegenerative diseases: molecular aspects."  CURRENT OPINION IN STRUCTURAL BIOLOGY, vol. 6, 1996, pages 848-858, XP002101177 cited in the application see the whole documentbut specially pages 853-856	1-6,8, 14,15
X	L. MANGIARINI ET AL.,: "Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice" CELL, vol. 87, 1996, pages 493-506, XP002101178 cited in the application see the whole document	2-6,23
Ą	WO 95 29243 A (UPJOHN CO ) 2 November 1995 see page 7, line 18 - page 11, line 30	1,8,15
A	EP 0 293 249 A (AMRAD CORP LTD) 30 November 1988 see abstract see page 2, column 2, line 40 - page 3, column 3, line 48 see page 8, column 13, line 36-51	1,8,15
<b>A</b>	K. STOTT ET AL.,: "Incorporation of glutamine repeats makes protein oligomerize: implications for neurodegenerative diseases" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 92, 1995, pages 6509-6513, XP002101179 cited in the application see the whole document	1,2,6,8

1





Internat | Application No PCT/EP 98/04811

X WO 96 28471 A (PHARM PEPTIDES INC) 19 September 1996 see abstract see page 3, line 5 - page 6, line 5 see page 7, line 10-26 see page 48, line 21 - page 53, line 15; examples 1,2  X MERLINI ET AL.,: "Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 92, 1995, pages 2959-2963, XP002101180 see the whole document  X KISILEVSKI ET AL.,: "Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer disease" NATURE MEDICINE, vol. 1, no. 2, 1995, pages 143-148, XP000611547 see the whole document  P,X DATABASE WPI Week 9824 Derwent Publications Ltd., London, GB; AN 98-272215 XP002101183 & WO 98 18920 A (SRL INC.), 7 May 1998 see abstract  P,X US 5 723 301 A (STRITTMATTER WARREN J ET AL) 3 March 1998 see the whole document  P,X E. SCHERZINGER ET AL.,: "Huntingtin-encoded polyglutamine expansions from amyloid-like protein aggregates in vitro and in vivo" CELL, vol. 90 8 August 1997, pages 549-558	Relevant to claim No.	WO 96 28471 A (PHARM PEPTIDES INC)
19 September 1996 see abstract see page 3, line 5 - page 6, line 5 see page 7, line 10-26 see page 7, line 10-26 see page 48, line 21 - page 53, line 15; examples 1,2  X MERLINI ET AL.,: "Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 92, 1995, pages 2959-2963, XP002101180 see the whole document  X KISILEVSKI ET AL.,: "Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer disease" NATURE MEDICINE, vol. 1, no. 2, 1995, pages 143-148, XP000611547 see the whole document  P,X DATABASE WPI Week 9824 Derwent Publications Ltd., London, GB; AN 98-272215 XP002101183 & WO 98 18920 A (SRL INC.), 7 May 1998 see abstract  P,X US 5 723 301 A (STRITTMATTER WARREN J ET AL) 3 March 1998 see the whole document  E. SCHERZINGER ET AL.,: "Huntingtin-encoded polyglutamine expansions from amyloid-like protein aggregates in vitro and in vivo" CELL,	20-22	
anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 92, 1995, pages 2959-2963, XP002101180 see the whole document  X  KISILEVSKI ET AL.,: "Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer disease" NATURE MEDICINE, vol. 1, no. 2, 1995, pages 143-148, XP000611547 see the whole document  P,X  DATABASE WPI Week 9824 Derwent Publications Ltd., London, GB; AN 98-272215 XP002101183 & WO 98 18920 A (SRL INC.), 7 May 1998 see abstract  P,X  US 5 723 301 A (STRITTMATTER WARREN J ET AL) 3 March 1998 see the whole document  P,X  E. SCHERZINGER ET AL.,: "Huntingtin-encoded polyglutamine expansions from amyloid-like protein aggregates in vitro and in vivo" CELL,		see abstract see page 3, line 5 - page 6, line 5 see page 7, line 10-26 see page 48, line 21 - page 53, line 15;
amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer disease" NATURE MEDICINE, vol. 1, no. 2, 1995, pages 143-148, XP000611547 see the whole document  P,X  DATABASE WPI Week 9824 Derwent Publications Ltd., London, GB; AN 98-272215 XP002101183 & WO 98 18920 A (SRL INC.), 7 May 1998 see abstract  P,X  US 5 723 301 A (STRITTMATTER WARREN J ET AL) 3 March 1998 see the whole document  P,X  E. SCHERZINGER ET AL.,: "Huntingtin-encoded polyglutamine expansions from amyloid-like protein aggregates in vitro and in vivo" CELL,	20-22	anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 92, 1995, pages 2959-2963, XP002101180
Week 9824 Derwent Publications Ltd., London, GB; AN 98-272215 XP002101183 & WO 98 18920 A (SRL INC.), 7 May 1998 see abstract  P,X US 5 723 301 A (STRITTMATTER WARREN J ET AL) 3 March 1998 see the whole document  P,X E. SCHERZINGER ET AL.,: "Huntingtin-encoded polyglutamine expansions from amyloid-like protein aggregates in vitro and in vivo" CELL,	20-22	amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer disease" NATURE MEDICINE, vol. 1, no. 2, 1995, pages 143-148, XP000611547
AL) 3 March 1998 see the whole document P,X E. SCHERZINGER ET AL.,: "Huntingtin-encoded polyglutamine expansions from amyloid-like protein aggregates in vitro and in vivo" CELL,	1,2,5, 9-13	Week 9824 Derwent Publications Ltd., London, GB; AN 98-272215 XP002101183 & WO 98 18920 A (SRL INC.), 7 May 1998
"Huntingtin-encoded polyglutamine expansions from amyloid-like protein aggregates in vitro and in vivo" CELL,	20-22	AL) 3 March 1998
XP002101181  cited in the application see the whole document	1-6, 8-12, 15-18, 20,22,23	"Huntingtin-encoded polyglutamine expansions from amyloid-like protein aggregates in vitro and in vivo" CELL, vol. 90, 8 August 1997, pages 549-558, XP002101181 cited in the application
-/		· -/

1



## INTERNATIONAL SEARCH REPORT

Internati | Application No

		PCT/EP 98/04811		
(Continue	ation) DOCUMENTS CONSIDERED TO BE RELEVANT			
alegory	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
Ρ,Χ	S.W. DAVIES ET AL., : "Formation of nuronal intrnuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation "CELL, vol. 90, 8 August 1997, pages 537-548, XP002101182 cited in the application see page 539, discussion and page 546.	1-6,13,		

1



Information on patent family members

Interna' 11 Application No PCT/EP 98/04811

#### Patent document Publication Patent family Publication cited in search report date member(s) date WO 9717445 FR Α 15-05-1997 2741088 A 16-05-1997 WO 9529243 Α 02-11-1995 AU 2355895 A 16-11-1995 EP 0758393 A 19-02-1997 JP 9512426 T 16-12-1997 EP 0293249 AT 30-11-1988 79902 T Α 15-09-1992 ΑU 607511 B 07-03-1991 ΑU 1793288 A 21-12-1988 WO 8809372 A 01-12-1988 CA 1338903 A 11-02-1997 DE 3873989 A 01-10-1992 DK 38189 A 27-01-1989 ES 16-01-1994 2045115 T 21-06-1993 GR 3006173 T JP 6081596 B 19-10-1994 JP 1503441 T 22-11-1989 NO 178894 B 18-03-1996 US 5654176 A 05-08-1997 WO 9628471 19-09-1996 US 5817626 A Α 06-10-1998 US 5854215 A 29-12-1998 ΑU 5252496 A 02-10-1996 CA 2214247 A 19-09-1996 EΡ 0815134 A 07-01-1998 US 5854204 A 29-12-1998 US 5723301 03-03-1998 NONE